← Back to screener

MoonLake Immunotherapeutics MLTX

Rank #1653 · Nasdaq · $0.9B market cap
⚠ Going-concern flag — the auditor (Baker Tilly US, LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
44.9
P/E
-24.1
P/B
1.94
ROE
-8.1%
Op. Margin
–%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -24.1x, P/B 1.94x. Ranks in the top 56% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -8.1%. Ranks in the top 76% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–––$0.0B–83
2021–$-0.0B$-0.0B$-0.0B–-165
2022–$-0.1B$-0.0B$-0.0B–-183
2023–$-0.1B$-0.0B$0.0B–17
2024–$-0.1B$-0.0B$0.5B–3
2025–$-0.1B$-0.0B$0.4B–5

← See the full screener